Even though the inhibitory effects of Ctx on GBM cells remains elusive with regards to etiology, Ctx remains clinically relevant for the potential management of GBM with three registered clinical trials within the United States [36–38]. The gene discussed is CYP27A1; the disease is glioblastoma.